Key Product Details
Product Summary for Human IGFBP‑6 Antibody
Accession # NP_002169
Scientific Data Images for Human IGFBP‑6 Antibody
IGFBP‑6 Inhibition of IGF‑II-dependent Cell Proliferation and Neutralization by Human IGFBP‑6 Antibody.Recombinant Human IGFBP-6 (Catalog # 876-B6) inhibits Recombinant Human IGF-II (Catalog # 292-G2) induced proliferation in the MCF-7 human breast cancer cell line in a dose-dependent manner (orange line). Inhibition of Recombinant Human IGF-II (14 ng/mL) activity elicited by Recombinant Human IGFBP-6 (0.8 µg/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IGFBP-6 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF876). The ND50 is typically 8-24 µg/mL.
Applications for Human IGFBP‑6 Antibody
Sample: Recombinant Human IGFBP‑6 (Catalog # 876-B6)
Read 2 reviews rated 2 using AF876 in the following applications:
Read 1 publication using AF876 in the following applications:
Formulation, Preparation and Storage
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Human IGFBP-6 cDNA encodes a 240 amino acid (aa) residue precursor protein with a putative 24 aa residue signal peptide that is processed to generate the 216 aa residue mature protein that is O-glycosylated. IGFBP-6 is expressed in ovarian cells, prostatic cells, and fibroblasts. IGFBP‑6 is found predominantly in CSF and serum. IGFBP-6 binds preferentially to IGF-II, exhibiting a 2-fold higher affinity for IGF-II than for IGF-I.
Product Specific Notices for Human IGFBP‑6 Antibody
For research use only